Movatterモバイル変換


[0]ホーム

URL:


SG11201401477XA - ANTI-HtrA1 ANTIBODIES AND METHODS OF USE - Google Patents

ANTI-HtrA1 ANTIBODIES AND METHODS OF USE

Info

Publication number
SG11201401477XA
SG11201401477XASG11201401477XASG11201401477XASG11201401477XASG 11201401477X ASG11201401477X ASG 11201401477XASG 11201401477X ASG11201401477X ASG 11201401477XASG 11201401477X ASG11201401477X ASG 11201401477XASG 11201401477X ASG11201401477X ASG 11201401477XA
Authority
SG
Singapore
Prior art keywords
methods
htra1 antibodies
htra1
antibodies
Prior art date
Application number
SG11201401477XA
Inventor
Yan Wu
Lookeren-Campagne Menno Van
Daniel Kirchhofer
Michael Terry Lipari
Jr Kenneth J Katschke
Paul M Moran
Scott Stawicki
Wei-Ching Liang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of SG11201401477XApublicationCriticalpatent/SG11201401477XA/en

Links

Classifications

Landscapes

SG11201401477XA2011-10-142012-10-12ANTI-HtrA1 ANTIBODIES AND METHODS OF USESG11201401477XA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201161547649P2011-10-142011-10-14
PCT/US2012/059878WO2013055998A1 (en)2011-10-142012-10-12ANTI-HtrA1 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication NumberPublication Date
SG11201401477XAtrue SG11201401477XA (en)2014-07-30

Family

ID=48082468

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201401477XASG11201401477XA (en)2011-10-142012-10-12ANTI-HtrA1 ANTIBODIES AND METHODS OF USE

Country Status (33)

CountryLink
US (3)US9738727B2 (en)
EP (2)EP3461839A1 (en)
JP (2)JP6532678B2 (en)
KR (2)KR20140082796A (en)
CN (2)CN108373506A (en)
AR (1)AR088322A1 (en)
AU (2)AU2012322618A1 (en)
BR (1)BR112014008862A2 (en)
CA (1)CA2850032C (en)
CL (1)CL2014000888A1 (en)
CO (1)CO7020870A2 (en)
CR (1)CR20140212A (en)
DK (1)DK2766393T3 (en)
EA (1)EA201490778A1 (en)
ES (1)ES2687951T3 (en)
HK (1)HK1255608A1 (en)
HR (1)HRP20181457T1 (en)
HU (1)HUE039133T2 (en)
IL (1)IL232055B (en)
LT (1)LT2766393T (en)
MA (1)MA35712B1 (en)
MX (2)MX390891B (en)
PE (1)PE20141562A1 (en)
PH (1)PH12014500841B1 (en)
PL (1)PL2766393T3 (en)
PT (1)PT2766393T (en)
RS (1)RS57645B1 (en)
SG (1)SG11201401477XA (en)
SI (1)SI2766393T1 (en)
TR (1)TR201811270T4 (en)
TW (1)TW201321414A (en)
WO (1)WO2013055998A1 (en)
ZA (1)ZA201402172B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CR20160132A (en)2013-08-122016-08-25Genentech Inc COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT
JP2017515811A (en)2014-05-012017-06-15ジェネンテック, インコーポレイテッド Anti-factor D antibody variants and methods of use thereof
CR20170240A (en)2014-11-102018-04-03Genentech Inc ANTI-INTERLEUCINA-33 ANTIBODIES AND THEIR USES
CN108472382A (en)2015-10-302018-08-31豪夫迈·罗氏有限公司Anti- factor D antibody variants conjugate and application thereof
US10407510B2 (en)2015-10-302019-09-10Genentech, Inc.Anti-factor D antibodies and conjugates
AU2016344133A1 (en)2015-10-302018-05-17Genentech, Inc.Anti-Factor D antibody formulations
KR102440160B1 (en)*2015-10-302022-09-02제넨테크, 인크.Anti-HtrA1 antibodies and methods of use thereof
US11377439B2 (en)2016-06-212022-07-05Orion Ophthalmology LLCHeterocyclic prolinamide derivatives
JP7164521B2 (en)2016-06-212022-11-01オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
JP2018096930A (en)*2016-12-162018-06-21公益財団法人ヒューマンサイエンス振興財団Diagnostic marker for age-related macular degeneration, diagnosis kit, method for supporting diagnosis, and method for determining risk of development
ES2966319T3 (en)*2016-12-222024-04-19Daiichi Sankyo Co Ltd Peptide for the treatment of age-related macular degeneration
WO2018183216A1 (en)2017-03-272018-10-04The Schepens Eye Research Institute, Inc.Notch3 agonist compositions and methods for treating small vessel diseases
WO2018183213A1 (en)2017-03-272018-10-04The Schepens Eye Research Institute, Inc.Blood biomarkers and diagnostic methods for small vessel diseases
EP3729095A1 (en)*2017-12-212020-10-28F. Hoffmann-La Roche AGCompanion diagnostic for htra1 rna antagonists
TW202015718A (en)*2018-06-212020-05-01日商第一三共股份有限公司 Peptide for treatment of retinitis pigmentosa
WO2020102680A1 (en)*2018-11-162020-05-22Gemini Therapeutics Inc.Antibody-based therapeutics for targeting htra1 and methods of use
WO2020109343A1 (en)2018-11-292020-06-04F. Hoffmann-La Roche AgCombination therapy for treatment of macular degeneration
TW202041533A (en)*2018-12-242020-11-16美商威特拉公司Methods for identifying epitopes and paratopes
CN113966401A (en)*2019-04-102022-01-21犹他大学研究基金会 HTRA1 modulation for the treatment of AMD
US11760797B2 (en)2020-03-132023-09-19Genentech, Inc.Anti-interleukin-33 antibodies and uses thereof
WO2022031680A1 (en)*2020-08-042022-02-10Exelixis, Inc.Cd47 binding agents and uses thereof
US20220251241A1 (en)*2021-02-082022-08-11Ngm Biopharmaceuticals, Inc.Htra1-binding agents and methods of use thereof

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3687808A (en)1969-08-141972-08-29Univ Leland Stanford JuniorSynthetic polynucleotides
US4376110A (en)1980-08-041983-03-08Hybritech, IncorporatedImmunometric assays using monoclonal antibodies
US4486530A (en)1980-08-041984-12-04Hybritech IncorporatedImmunometric assays using monoclonal antibodies
US4469863A (en)1980-11-121984-09-04Ts O Paul O PNonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4485045A (en)1981-07-061984-11-27Research CorporationSynthetic phosphatidyl cholines useful in forming liposomes
CA1188246A (en)1981-08-311985-06-04Jerry L. GregoryImmobilized microbe recycle apparatus
US5023243A (en)1981-10-231991-06-11Molecular Biosystems, Inc.Oligonucleotide therapeutic agent and method of making same
US4476301A (en)1982-04-291984-10-09Centre National De La Recherche ScientifiqueOligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4522811A (en)1982-07-081985-06-11Syntex (U.S.A.) Inc.Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NZ207394A (en)1983-03-081987-03-06Commw Serum Lab CommissionDetecting or determining sequence of amino acids
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US4544545A (en)1983-06-201985-10-01Trustees University Of MassachusettsLiposomes containing modified cholesterol for organ targeting
US5118800A (en)1983-12-201992-06-02California Institute Of TechnologyOligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en)1984-07-111996-08-27Temple University-Of The Commonwealth System Of Higher EducationDual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en)1984-07-191989-02-17Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5367066A (en)1984-10-161994-11-22Chiron CorporationOligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (en)1985-01-081987-04-03Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5185444A (en)1985-03-151993-02-09Anti-Gene Deveopment GroupUncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en)1985-03-151993-08-10Anti-Gene Development GroupAlpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en)1985-03-151991-07-23Anti-Gene Development GroupUncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en)1989-12-201995-04-11Anti-Gene Development GroupSequence-specific binding polymers for duplex nucleic acids
US4737456A (en)1985-05-091988-04-12Syntex (U.S.A.) Inc.Reducing interference in ligand-receptor binding assays
US4676980A (en)1985-09-231987-06-30The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesTarget specific cross-linked heteroantibodies
US4868105A (en)1985-12-111989-09-19Chiron CorporationSolution phase nucleic acid sandwich assay
US6548640B1 (en)1986-03-272003-04-15Btg International LimitedAltered antibodies
US4987071A (en)1986-12-031991-01-22University Patents, Inc.RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)1987-03-181990-08-16Sb2, Inc.Altered antibodies
US5276019A (en)1987-03-251994-01-04The United States Of America As Represented By The Department Of Health And Human ServicesInhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en)1987-03-251993-11-23The United States Of America As Represented By The Department Of Health And Human ServicesInhibitors for replication of retroviruses and for the expression of oncogene products
US4924624A (en)1987-10-221990-05-15Temple University-Of The Commonwealth System Of Higher Education2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en)1987-10-221993-02-23Temple University Of The Commonwealth System Of Higher EducationEncapsulated 2',5'-phosphorothioate oligoadenylates
US5606040A (en)1987-10-301997-02-25American Cyanamid CompanyAntitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en)1987-10-301998-06-23American Cyanamid CompanyProcess for preparing targeted forms of methyltrithio antitumor agents
IE61148B1 (en)1988-03-101994-10-05Ici PlcMethod of detecting nucleotide sequences
WO1989009221A1 (en)1988-03-251989-10-05University Of Virginia Alumni Patents FoundationOligonucleotide n-alkylphosphoramidates
US5278302A (en)1988-05-261994-01-11University Patents, Inc.Polynucleotide phosphorodithioates
US5216141A (en)1988-06-061993-06-01Benner Steven AOligonucleotide analogs containing sulfur linkages
US5175273A (en)1988-07-011992-12-29Genentech, Inc.Nucleic acid intercalating agents
GB8823869D0 (en)1988-10-121988-11-16Medical Res CouncilProduction of antibodies
EP0368684B2 (en)1988-11-112004-09-29Medical Research CouncilCloning immunoglobulin variable domain sequences.
US5047335A (en)1988-12-211991-09-10The Regents Of The University Of Calif.Process for controlling intracellular glycosylation of proteins
DE3920358A1 (en)1989-06-221991-01-17Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
JP3058686B2 (en)1989-08-312000-07-04シティ・オブ・ホープ Chimeric DNA-RNA catalytically active sequence
US5591722A (en)1989-09-151997-01-07Southern Research Institute2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5013556A (en)1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
US5399676A (en)1989-10-231995-03-21Gilead SciencesOligonucleotides with inverted polarity
US5264564A (en)1989-10-241993-11-23Gilead SciencesOligonucleotide analogs with novel linkages
US5264562A (en)1989-10-241993-11-23Gilead Sciences, Inc.Oligonucleotide analogs with novel linkages
ATE190981T1 (en)1989-10-242000-04-15Isis Pharmaceuticals Inc 2'-MODIFIED NUCLEOTIDES
US5208020A (en)1989-10-251993-05-04Immunogen Inc.Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en)1989-10-252006-02-07Ravi J. ChariCytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)1989-10-271999-09-28The Scripps Research InstituteTransgenic plants expressing assembled secretory antibodies
US5177198A (en)1989-11-301993-01-05University Of N.C. At Chapel HillProcess for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en)1989-12-201992-07-14Boron Bilogicals, Inc.Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en)1990-01-111995-10-17Isis Pharmaceuticals, Inc.N-2 substituted purines
US5587361A (en)1991-10-151996-12-24Isis Pharmaceuticals, Inc.Oligonucleotides having phosphorothioate linkages of high chiral purity
US5646265A (en)1990-01-111997-07-08Isis Pharmceuticals, Inc.Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5587470A (en)1990-01-111996-12-24Isis Pharmaceuticals, Inc.3-deazapurines
US5670633A (en)1990-01-111997-09-23Isis Pharmaceuticals, Inc.Sugar modified oligonucleotides that detect and modulate gene expression
US5681941A (en)1990-01-111997-10-28Isis Pharmaceuticals, Inc.Substituted purines and oligonucleotide cross-linking
US6150584A (en)1990-01-122000-11-21Abgenix, Inc.Human antibodies derived from immunized xenomice
US6075181A (en)1990-01-122000-06-13Abgenix, Inc.Human antibodies derived from immunized xenomice
US5321131A (en)1990-03-081994-06-14Hybridon, Inc.Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)1990-04-101995-11-28The Dupont Merck Pharmaceutical CompanyOligonucleotide analogs with sulfamate linkages
GB9009980D0 (en)1990-05-031990-06-27Amersham Int PlcPhosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (en)1990-05-111998-08-01Microprobe Corp SOLID SUPPORTS FOR NUCLEIC ACID HYBRIDIZATION TESTS AND METHODS TO IMMOBILIZE OLIGONUCLEOTIDES IN A COVALENT WAY.
US5608046A (en)1990-07-271997-03-04Isis Pharmaceuticals, Inc.Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en)1990-07-271997-03-11Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogues
US5489677A (en)1990-07-271996-02-06Isis Pharmaceuticals, Inc.Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5677437A (en)1990-07-271997-10-14Isis Pharmaceuticals, Inc.Heteroatomic oligonucleoside linkages
US5541307A (en)1990-07-271996-07-30Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5618704A (en)1990-07-271997-04-08Isis Pharmacueticals, Inc.Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5602240A (en)1990-07-271997-02-11Ciba Geigy Ag.Backbone modified oligonucleotide analogs
US5623070A (en)1990-07-271997-04-22Isis Pharmaceuticals, Inc.Heteroatomic oligonucleoside linkages
AU667459B2 (en)1990-08-031996-03-28SanofiCompounds and methods for inhibiting gene expression
US5177196A (en)1990-08-161993-01-05Microprobe CorporationOligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
KR100272077B1 (en)1990-08-292000-11-15젠팜인터내셔날,인코포레이티드Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)1990-08-291998-06-23Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)1990-08-291997-05-27Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)1990-08-291997-08-26Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)1990-08-291997-04-29Genpharm International, Inc.Transgenic non-human animals for producing heterologous antibodies
US5214134A (en)1990-09-121993-05-25Sterling Winthrop Inc.Process of linking nucleosides with a siloxane bridge
US5561225A (en)1990-09-191996-10-01Southern Research InstitutePolynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en)1990-09-201997-01-21Gilead Sciences, Inc.Modified internucleoside linkages having one nitrogen and two carbon atoms
US5432272A (en)1990-10-091995-07-11Benner; Steven A.Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JP3257675B2 (en)1990-10-122002-02-18マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー.ファウ. Modified ribozyme
CA2095633C (en)1990-12-032003-02-04Lisa J. GarrardEnrichment method for variant proteins with altered binding properties
US5571894A (en)1991-02-051996-11-05Ciba-Geigy CorporationRecombinant antibodies specific for a growth factor receptor
US5278299A (en)1991-03-181994-01-11Scripps Clinic And Research FoundationMethod and composition for synthesizing sialylated glycosyl compounds
US5539082A (en)1993-04-261996-07-23Nielsen; Peter E.Peptide nucleic acids
US5714331A (en)1991-05-241998-02-03Buchardt, Deceased; OlePeptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
DE4216134A1 (en)1991-06-201992-12-24Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
GB9114948D0 (en)1991-07-111991-08-28Pfizer LtdProcess for preparing sertraline intermediates
US5571799A (en)1991-08-121996-11-05Basco, Ltd.(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US7018809B1 (en)1991-09-192006-03-28Genentech, Inc.Expression of functional antibody fragments
DE69229477T2 (en)1991-09-231999-12-09Cambridge Antibody Technology Ltd., Melbourn Methods for the production of humanized antibodies
US5587458A (en)1991-10-071996-12-24Aronex Pharmaceuticals, Inc.Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ES2103918T3 (en)1991-10-171997-10-01Ciba Geigy Ag BICYCLE NUCLEOSIDES, OLIGONUCLEOTIDES, PROCEDURE FOR THEIR OBTAINING AND INTERMEDIATE PRODUCTS.
WO1993008829A1 (en)1991-11-041993-05-13The Regents Of The University Of CaliforniaCompositions that mediate killing of hiv-infected cells
US5594121A (en)1991-11-071997-01-14Gilead Sciences, Inc.Enhanced triple-helix and double-helix formation with oligomers containing modified purines
WO1993010260A1 (en)1991-11-211993-05-27The Board Of Trustees Of The Leland Stanford Junior UniversityControlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5484908A (en)1991-11-261996-01-16Gilead Sciences, Inc.Oligonucleotides containing 5-propynyl pyrimidines
US5652094A (en)1992-01-311997-07-29University Of MontrealNucleozymes
FR2687679B1 (en)1992-02-051994-10-28Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
CA2372813A1 (en)1992-02-061993-08-19L.L. HoustonBiosynthetic binding protein for cancer marker
US5434257A (en)1992-06-011995-07-18Gilead Sciences, Inc.Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (en)1992-07-011994-01-05Ciba-Geigy AgCarbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
ATE196606T1 (en)1992-11-132000-10-15Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA
US5635483A (en)1992-12-031997-06-03Arizona Board Of Regents Acting On Behalf Of Arizona State UniversityTumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)1993-01-261998-07-14Arizona Board Of RegentsElucidation and synthesis of selected pentapeptides
US5476925A (en)1993-02-011995-12-19Northwestern UniversityOligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en)1993-03-061993-04-21Ciba Geigy AgChemical compounds
AU6449394A (en)1993-03-301994-10-24Sterling Winthrop Inc.Acyclic nucleoside analogs and oligonucleotide sequences containing them
CA2159629A1 (en)1993-03-311994-10-13SanofiOligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (en)1993-04-101994-10-13Degussa Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
CA2163345A1 (en)1993-06-161994-12-22Susan Adrienne MorganAntibodies
WO1995007330A1 (en)1993-09-091995-03-16The Procter & Gamble CompanyAutomatic dishwashing detergent with alkoxy or aryloxy amide surfactant
US5502177A (en)1993-09-171996-03-26Gilead Sciences, Inc.Pyrimidine derivatives for labeled binding partners
US5446137B1 (en)1993-12-091998-10-06Behringwerke AgOligonucleotides containing 4'-substituted nucleotides
US5596091A (en)1994-03-181997-01-21The Regents Of The University Of CaliforniaAntisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en)1994-03-291997-05-06Ribozyme Pharmaceuticals, Inc.2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en)1994-03-311997-04-29Amgen Inc.Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en)1994-05-181996-06-11The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesPteridine nucleotide analogs as fluorescent DNA probes
US5773001A (en)1994-06-031998-06-30American Cyanamid CompanyConjugates of methyltrithio antitumor agents and intermediates for their synthesis
AU2766195A (en)1994-06-031996-01-05Brigham And Women's HospitalIdentification of polycystic kidney disease gene, diagnostics and treatment
US5789199A (en)1994-11-031998-08-04Genentech, Inc.Process for bacterial production of polypeptides
US5840523A (en)1995-03-011998-11-24Genetech, Inc.Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
US5869046A (en)1995-04-141999-02-09Genentech, Inc.Altered polypeptides with increased half-life
US5739277A (en)1995-04-141998-04-14Genentech Inc.Altered polypeptides with increased half-life
US5712374A (en)1995-06-071998-01-27American Cyanamid CompanyMethod for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)1995-06-071998-02-03American Cyanamid CompanyMethods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU6180696A (en)1995-06-211997-01-22Martek Biosciences CorporationCombinatorial libraries of labeled biochemical compounds and methods for producing same
US6267958B1 (en)1995-07-272001-07-31Genentech, Inc.Protein formulation
US5837492A (en)1995-12-181998-11-17Myriad Genetics, Inc.Chromosome 13-linked breast cancer susceptibility gene
GB9603256D0 (en)1996-02-161996-04-17Wellcome FoundAntibodies
US6274376B1 (en)1996-02-202001-08-14Smithkline Beecham CorporationClpL
EP0828003A3 (en)1996-09-062003-01-15SmithKline Beecham plcHuman serine protease
US5800998A (en)1996-11-121998-09-01Millennium Pharmaceuticals, Inc.Assays for diagnosing type II diabetes in a subject
JP2001505060A (en)1997-01-142001-04-17ヒューマン ジノーム サイエンシーズ,インコーポレイテッド Tumor necrosis factor receptor 5
US6171586B1 (en)1997-06-132001-01-09Genentech, Inc.Antibody formulation
PT994903E (en)1997-06-242005-10-31Genentech Inc METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS
AR013269A1 (en)1997-08-042000-12-13Scras PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS
US6040498A (en)1998-08-112000-03-21North Caroline State UniversityGenetically engineered duckweed
WO1999022764A1 (en)1997-10-311999-05-14Genentech, Inc.Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)1997-11-242003-08-26The Institute For Human Genetics And BiochemistryMonoclonal human natural antibodies
ES2375931T3 (en)1997-12-052012-03-07The Scripps Research Institute HUMANIZATION OF ANTIBODY MURINO.
US6506559B1 (en)1997-12-232003-01-14Carnegie Institute Of WashingtonGenetic inhibition by double-stranded RNA
US6274720B1 (en)1997-12-312001-08-14Incyte Genomics, Inc.Human preproneurotensin/neuromedin N
WO1999051642A1 (en)1998-04-021999-10-14Genentech, Inc.Antibody variants and fragments thereof
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
AU3657899A (en)1998-04-201999-11-08James E. BaileyGlycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU3669499A (en)1998-04-281999-11-16Axys Pharmaceuticals, Inc.Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
GB9827152D0 (en)1998-07-031999-02-03Devgen NvCharacterisation of gene function using double stranded rna inhibition
AU5290499A (en)1998-08-032000-02-28Novartis AgHuman htra serine protease
HUP0104865A3 (en)1999-01-152004-07-28Genentech IncPolypeptide variants with altered effector function
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
EP1147204A1 (en)1999-01-282001-10-24Medical College Of Georgia Research Institute, Inc.Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en)1999-01-302000-08-17Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
EP3031917A1 (en)1999-04-092016-06-15Kyowa Hakko Kirin Co., Ltd.Method for controlling the activity of immunologically functional molecule
US7125978B1 (en)1999-10-042006-10-24Medicago Inc.Promoter for regulating expression of foreign genes
ATE303445T1 (en)1999-10-042005-09-15Medicago Inc METHOD FOR REGULATION OF TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
EP1235842A4 (en)1999-10-152003-04-23Univ Massachusetts GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
JP4668498B2 (en)1999-10-192011-04-13協和発酵キリン株式会社 Method for producing polypeptide
GB9927444D0 (en)1999-11-192000-01-19Cancer Res Campaign TechInhibiting gene expression
IL149809A0 (en)1999-12-152002-11-10Genentech IncShotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531821A (en)1999-12-292003-10-28イムノージェン インコーポレーテッド Cytotoxic drugs containing modified doxorubicin and daunorubicin and their therapeutic use
HUP0300369A2 (en)2000-04-112003-06-28Genentech, Inc.Multivalent antibodies and uses therefor
WO2002031140A1 (en)2000-10-062002-04-18Kyowa Hakko Kogyo Co., Ltd.Cells producing antibody compositions
US7064191B2 (en)2000-10-062006-06-20Kyowa Hakko Kogyo Co., Ltd.Process for purifying antibody
US6946292B2 (en)2000-10-062005-09-20Kyowa Hakko Kogyo Co., Ltd.Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en)2000-10-312003-07-22Regeneron Pharmaceuticals, Inc.Methods of modifying eukaryotic cells
CA2430013C (en)2000-11-302011-11-22Medarex, Inc.Transgenic transchromosomal rodents for making human antibodies
AUPR670701A0 (en)2001-07-302001-08-23Prince Henry's Institute Of Medical ResearchNovel serine protease
NZ581474A (en)2001-08-032011-04-29Glycart Biotechnology AgAntibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE430580T1 (en)2001-10-252009-05-15Genentech Inc GLYCOPROTEIN COMPOSITIONS
JP2003135075A (en)2001-11-052003-05-13Research Association For BiotechnologyNEW FULL-LENGTH cDNA
US20040093621A1 (en)2001-12-252004-05-13Kyowa Hakko Kogyo Co., LtdAntibody composition which specifically binds to CD20
ES2362419T3 (en)2002-04-092011-07-05Kyowa Hakko Kirin Co., Ltd. CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
CA2481920A1 (en)2002-04-092003-10-16Kyowa Hakko Kogyo Co., Ltd.Antibody composition-containing medicament
MXPA04009924A (en)2002-04-092005-07-01Kyowa Hakko Kogyo KkCells with modified genome.
US20040259150A1 (en)2002-04-092004-12-23Kyowa Hakko Kogyo Co., Ltd.Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1502603A4 (en)2002-04-092006-12-13Kyowa Hakko Kogyo KkDRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM
WO2003085118A1 (en)2002-04-092003-10-16Kyowa Hakko Kogyo Co., Ltd.Process for producing antibody composition
CA2488441C (en)2002-06-032015-01-27Genentech, Inc.Synthetic antibody phage libraries
US7361740B2 (en)2002-10-152008-04-22Pdl Biopharma, Inc.Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (en)2002-12-162012-12-31Genentech IncImmunoglobulin variants and uses thereof
CA2510003A1 (en)2003-01-162004-08-05Genentech, Inc.Synthetic antibody phage libraries
US20060104968A1 (en)2003-03-052006-05-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en)2003-03-052011-01-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2005035586A1 (en)2003-10-082005-04-21Kyowa Hakko Kogyo Co., Ltd.Fused protein composition
AU2004280065A1 (en)2003-10-092005-04-21Kyowa Hakko Kirin Co., Ltd.Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
MX337587B (en)2003-11-052016-03-11Glycart Biotechnology AgAntigen binding molecules with increased fc receptor binding affinity and effector function.
SG10201701737XA (en)2003-11-062017-04-27Seattle Genetics IncMonomethylvaline compounds capable of conjugation to ligands
JP2005154399A (en)*2003-11-242005-06-16Nara Institute Of Science & Technology Use of serine protease HtrA
WO2005053742A1 (en)2003-12-042005-06-16Kyowa Hakko Kogyo Co., Ltd.Medicine containing antibody composition
US7527791B2 (en)2004-03-312009-05-05Genentech, Inc.Humanized anti-TGF-beta antibodies
US7785903B2 (en)2004-04-092010-08-31Genentech, Inc.Variable domain library and uses
EP2357201B1 (en)2004-04-132017-08-30F. Hoffmann-La Roche AGAnti-P-selectin antibodies
TWI309240B (en)2004-09-172009-05-01Hoffmann La RocheAnti-ox40l antibodies
ES2669510T3 (en)2004-09-232018-05-28Genentech, Inc. Antibodies and conjugates engineered with cysteine
JO3000B1 (en)2004-10-202016-09-05Genentech IncAntibody Formulations.
US7695909B2 (en)2005-06-082010-04-13University Of Pittsburgh-Of The Commonwealth System Of Higher EducationSusceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
EP1957531B1 (en)2005-11-072016-04-13Genentech, Inc.Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en)2005-12-022007-06-07Genentech, Inc.Binding polypeptides with restricted diversity sequences
AR060871A1 (en)2006-05-092008-07-16Genentech Inc UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
DK2059533T3 (en)2006-08-302013-02-25Genentech Inc MULTI-SPECIFIC ANTIBODIES
WO2008067040A2 (en)2006-10-062008-06-05University Of Utah Research FoundationMethod of detecting ocular diseases and pathologic conditions and treatment of same
EP2097448A4 (en)2006-12-222010-07-21Univ Utah Res Found METHOD FOR DETECTING DISEASES AND OCULAR DISEASE CONDITIONS AND TREATMENT THEREOF
US20080226635A1 (en)2006-12-222008-09-18Hans KollAntibodies against insulin-like growth factor I receptor and uses thereof
CL2008000493A1 (en)2007-02-162008-06-27Genentech Inc POLYPEPTIDE THAT SPECIFICALLY JOINS A PDZ DOMAIN OF PROTEIN HTRA1; POLINUCLEOTIDE THAT CODIFIES IT; METHOD OF PRODUCTION; ANTIBODY THAT JOINS HIM; AND ITS USE TO TREAT PATHOLOGIES RELATED TO THE HTRA1 PROTEIN.
WO2008103299A2 (en)*2007-02-162008-08-28Massachusetts Eye & Ear InfirmaryMethods and compositions for prognosing, detecting, and treating age-related macular degeneration
CN100592373C (en)2007-05-252010-02-24群康科技(深圳)有限公司Liquid crystal panel drive device and its drive method
WO2009046405A2 (en)*2007-10-052009-04-09University Of Utah Research FoundationAntibodies to htra1 and methods of using the same
DK2235064T3 (en)2008-01-072016-01-11Amgen IncA process for the preparation of heterodimeric Fc molecules using electrostatic control effects
CN101550451B (en)*2008-03-042011-08-31四川省医学科学院(四川省人民医院)Reagent kit for detecting agedness yellow spot degenerative disease
US9925398B2 (en)*2008-04-232018-03-27Novacell Technology Inc.Angiogenic peptide
MX2011004763A (en)*2008-11-052011-06-01Genentech IncGenetic polymorphisms in age-related macular degeneration.

Also Published As

Publication numberPublication date
JP2015501149A (en)2015-01-15
CR20140212A (en)2014-06-19
PL2766393T3 (en)2018-11-30
CA2850032C (en)2022-06-07
MX2014004022A (en)2014-04-30
EP2766393A4 (en)2015-07-01
TW201321414A (en)2013-06-01
NZ623346A (en)2016-09-30
AR088322A1 (en)2014-05-28
LT2766393T (en)2018-10-10
PT2766393T (en)2018-10-15
EP3461839A1 (en)2019-04-03
CN108373506A (en)2018-08-07
ZA201402172B (en)2015-08-26
WO2013055998A1 (en)2013-04-18
KR102102862B1 (en)2020-04-22
PH12014500841A1 (en)2014-06-09
ES2687951T3 (en)2018-10-30
IL232055B (en)2020-11-30
PH12014500841B1 (en)2019-11-29
AU2017236046B2 (en)2019-08-15
US20170342163A1 (en)2017-11-30
CN103917556B (en)2018-02-06
CA2850032A1 (en)2013-04-18
US20130129743A1 (en)2013-05-23
RS57645B1 (en)2018-11-30
KR20200010575A (en)2020-01-30
HUE039133T2 (en)2018-12-28
US20190016826A1 (en)2019-01-17
HK1255608A1 (en)2019-08-23
DK2766393T3 (en)2018-10-01
AU2017236046C1 (en)2020-01-23
CO7020870A2 (en)2014-08-11
CN103917556A (en)2014-07-09
AU2012322618A1 (en)2014-05-29
EP2766393A1 (en)2014-08-20
MX372661B (en)2020-05-04
MX390891B (en)2025-03-19
EA201490778A1 (en)2014-09-30
IL232055A0 (en)2014-05-28
BR112014008862A2 (en)2018-08-07
AU2017236046A1 (en)2017-10-26
KR20140082796A (en)2014-07-02
SI2766393T1 (en)2018-10-30
MA35712B1 (en)2014-12-01
CL2014000888A1 (en)2014-07-25
JP6532678B2 (en)2019-06-19
PE20141562A1 (en)2014-11-12
TR201811270T4 (en)2018-08-27
EP2766393B1 (en)2018-07-18
HRP20181457T1 (en)2018-11-16
US9738727B2 (en)2017-08-22
JP2018046832A (en)2018-03-29

Similar Documents

PublicationPublication DateTitle
HRP20181457T1 (en)ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
ZA201403760B (en)Anti-cd98 antibodies and methods of use thereof
ZA201501858B (en)Anti-mcam antibodies and associated methods of use
HK1213581A1 (en)Anti-cd40 antibodies and methods of use -cd40
ZA201308022B (en)Anti-cd40 antibodies and methods of use
HK1201843A1 (en)Anti-polyubiquitin antibodies and methods of use
HK1205517A1 (en)Anti sez6 antibodies and methods of use sez6
HK1205195A1 (en)Cd47 antibodies and methods of use thereof cd47
IL238227A0 (en)Anti-c16orf54 antibodies and methods of use thereof
ZA201404675B (en)Anti-lrp5 antibodies and methods of use
HK1182117A1 (en)Anti-tenascin-c a2 antibodies and methods of use -c a2
ZA201401653B (en)Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2734234A4 (en)Anti-cxcr4 antibodies and methods of use
ZA201300174B (en)Anti-neuropilin antibodies and methods of use
HK1209432A1 (en)Anti-jagged antibodies and methods of use
HK1201537A1 (en)Anti-kdr antibodies and methods of use -kdr
EP2709999A4 (en)Quinazoline-7-ether compounds and methods of use
HK1199040A1 (en)Use of antibody
HK1184173A1 (en)Anti-kdr antibodies and methods of use -kdr
EP2776462A4 (en)Indolealkylamino-withasteroid conjugates and method of use

[8]ページ先頭

©2009-2025 Movatter.jp